Skip to main content

Trispecific Antibody Deal Benchmarks in Hematology

Median Upfront
$597M
Range: $311M - $879M
Total Deal Value
$3.0B
Range: $1.8B - $4.1B
Royalty Rate
8.5% - 16%
Tiered up to 20%
Dev Milestones
$501M
Range: $323M - $680M
Model Your Deal

Market Analysis

Trispecific Antibody therapies in hematology have seen significant M&A and licensing activity in recent years. Based on analysis of 1,500+ verified transactions, the median upfront payment for a Phase 2 trispecific antibody asset in hematology is $597M, with total deal values reaching $3.0B. Development milestones average $501M, while regulatory milestones contribute $597M.

The hematology trispecific antibody landscape is characterized by high competitive intensity in lymphoma and myeloma with established treatment paradigms. Bispecific antibodies and next-generation cell therapies are displacing traditional chemotherapy combinations. The recommended deal structure allocates approximately 20% to upfront payments and 80% to milestones, reflecting the risk-reward profile at the Phase 2 stage.

Royalty rates for trispecific antibody hematology deals range from 8.5% to 16% at the base tier, with tiered escalation reaching 12.5%-20% on blockbuster sales. Commercial milestones averaging $1.3B further reward successful market penetration.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the typical upfront for a trispecific antibody hematology licensing deal?
Based on our analysis, Phase 2 trispecific antibody licensing deals in hematology average $597M in upfront payments, with a range of $311M to $879M depending on data quality, competitive positioning, and territorial scope.
What is the total deal value for trispecific antibody hematology transactions?
The median total deal value for Phase 2 trispecific antibody assets in hematology is $3.0B, ranging from $1.8B to $4.1B. This includes development milestones ($501M), regulatory milestones ($597M), and commercial milestones ($1.3B).
What royalty rates are standard for trispecific antibody deals in hematology?
Base royalty rates for trispecific antibody hematology transactions range from 8.5% to 16%, with tiered escalations reaching 12.5%-20% on peak sales. Rates are influenced by mechanism differentiation, competitive landscape, and territorial scope.
How are milestones structured in trispecific antibody hematology deals?
Trispecific Antibody hematology deals allocate approximately 80% of total deal value to milestones. Development milestones ($501M) make up the largest share, followed by commercial milestones ($1.3B) and regulatory milestones ($597M).
PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Related Benchmarks

CAR-T (Hematologic) in Hematology

View

Bispecific Antibody in Hematology

View

Trispecific Antibody in Oncology

View

Trispecific Antibody in Neurology

View

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.

Start Calculating
For Funds & Advisors

Need the full deal landscape?

The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.

Configure Brief — $2,500All-inclusive · White-label · Walkthrough included